How to buy Akebia Therapeutics (AKBA) stock

Akebia Therapeutics, Inc is a biotechnology business based in the US. Akebia Therapeutics shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Therapeutics employs 379 staff and has a trailing 12-month revenue of around 0.00.

Akebia Therapeutics stock price (NASDAQ: AKBA)

Use our graph to track the performance of AKBA stocks over time.

Akebia Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$3.51
52-week range	$2.09 - $12.48
50-day moving average	$3.54
200-day moving average	$3.46
Wall St. target price	$6.57
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.40

Buy Akebia Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Akebia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Akebia Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akebia Therapeutics price performance over time

Historical closes compared with the close of $3.51 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-13.97%
3 months (2021-04-28)	9.69%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Akebia Therapeutics financials

Revenue TTM	$259.1 million
Gross profit TTM	$12.9 million
Return on assets TTM	-14.83%
Return on equity TTM	-128.57%
Profit margin	-151.39%
Book value	$1.35
Market capitalisation	$432.3 million

TTM: trailing 12 months

Shorting Akebia Therapeutics shares

There are currently 15.3 million Akebia Therapeutics shares held short by investors – that's known as Akebia Therapeutics's "short interest". This figure is 2.2% down from 15.6 million last month.

There are a few different ways that this level of interest in shorting Akebia Therapeutics shares can be evaluated.

Akebia Therapeutics's "short interest ratio" (SIR)

Akebia Therapeutics's "short interest ratio" (SIR) is the quantity of Akebia Therapeutics shares currently shorted divided by the average quantity of Akebia Therapeutics shares traded daily (recently around 4.2 million). Akebia Therapeutics's SIR currently stands at 3.61. In other words for every 100,000 Akebia Therapeutics shares traded daily on the market, roughly 3610 shares are currently held short.

However Akebia Therapeutics's short interest can also be evaluated against the total number of Akebia Therapeutics shares, or, against the total number of tradable Akebia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akebia Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Akebia Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.0963% of the tradable shares (for every 100,000 tradable Akebia Therapeutics shares, roughly 96 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akebia Therapeutics.

Find out more about how you can short Akebia Therapeutics stock.

Akebia Therapeutics share dividends

We're not expecting Akebia Therapeutics to pay a dividend over the next 12 months.

Akebia Therapeutics share price volatility

Over the last 12 months, Akebia Therapeutics's shares have ranged in value from as little as $2.09 up to $12.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Therapeutics's is 1.7437. This would suggest that Akebia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Akebia Therapeutics overview

Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.

Frequently asked questions

What percentage of Akebia Therapeutics is owned by insiders or institutions?
Currently 1.137% of Akebia Therapeutics shares are held by insiders and 64.728% by institutions. How many people work for Akebia Therapeutics?
Latest data suggests 379 work at Akebia Therapeutics. When does the fiscal year end for Akebia Therapeutics?
Akebia Therapeutics's fiscal year ends in December. Where is Akebia Therapeutics based?
Akebia Therapeutics's address is: 245 First Street, Cambridge, MA, United States, 02142 What is Akebia Therapeutics's ISIN number?
Akebia Therapeutics's international securities identification number is: US00972D1054 What is Akebia Therapeutics's CUSIP number?
Akebia Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00972D105